Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 26, Issue 1, Pages 22-29Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2014.10.002
Keywords
beta Klotho; brown adipose tissue; hypothalamus; sympathetic nervous system; arginine vasopressin; corticotropin-releasing factor
Categories
Funding
- National Institutes of Health [R01DK067158]
- Robert A. Welch Foundation [I-1558, I-1275]
- Howard Hughes Medical Institute
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067158] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with beta Klotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
